Search clinical trials for: BI-1206 single agent expansion phase

Total 153 results

Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
AtlasMedx, Incorporated

Active, not recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Homologous Recombination Deficiency | Advanced Malignant Neoplasm

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Avenge Bio, Inc

Terminated

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Primary Peritoneal Carcinoma | Neoplasm, Ovarian | Adenocarcinoma Ovary | Serous Adenocarcinoma of Ovary | Serous Adenocarcinoma of Primary Peritoneum | High Grade Serous Adenocarcinoma

United States
Institut Curie

Recruiting

First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)

Metastatic Solid Tumor Cancer

France
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
Louisiana State University Health Sciences Center...

Terminated

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

United States
University of Kansas Medical Center
In8bio Inc.

Recruiting

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
University of Oxford
University of Copenhagen; Zimmer Biomet

Unknown

All Ligaments Left In Knee Arthroplasty Trial (ALLIKAT)

Primary Osteoarthritis of Knee Nos

United Kingdom
Pfizer

Completed

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Arthritis, Rheumatoid

Australia, United States, Austria, Germany, Ireland, Brazil, Spain, Taiwan, Belgium, Canada, France, Italy, Korea, Republic of, Puerto Rico
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
National Institute of Cardiology, Warsaw, Poland

Recruiting

Optimal Medical Treatment of Difficult-to-treat Hypertension (OPTIMAL-HT)

Hypertension

Poland
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Beijing Bio-Fortune Ltd.

Completed

Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers

Healthy Volunteers

China
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
University of Michigan
Food and Drug Administration (FDA)

Completed

Correlation of Mesalamine Pharmacokinetics With Local Availability

Local Drug Concentration in Gastrointestinal Tract

United States
AnHeart Therapeutics Inc.

Completed

Study the Effect of Omeprazole on AB-106 Pharmacokinetics

Pharmacokinetic Study

China
EMD Serono

Completed

Relative Bioavailability of Pimasertib in Cancer Patients

Neoplasms

United States
Boehringer Ingelheim

Completed

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Healthy

Germany
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Singapore, Taiwan
Auzone Biological Technology Pty Ltd
TIGERMED AUSTRALIA PTY LIMITED; CMAX Clinical Research Pty Ltd

Completed

A Study of TTYP01 in Healthy Adult Subjects

Healthy Adult Subjects

Australia
Medical College of Wisconsin
University of Oklahoma

Recruiting

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage (TheoPHyLNNe)

Acute Kidney Injury | HIE

United States
Pfizer

Completed

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Urinary Bladder, Neurogenic

France, United States, Spain, Korea, Republic of, United Kingdom, Malaysia, Taiwan, Finland, Japan, Lithuania, Italy, Turkey, Estonia, Slovakia, Belgium, Canada, Germany, Greece, India, Philippines, Poland, Russian Federation, South... and more
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Major Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland Carcinoma

United States
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Swiss Federal Institute of Technology

Completed

The Optimization of Bioavailability From Iron Supplements: Study 2

Anemia | Iron Deficiency Anemia | Iron Deficiency

Switzerland
Boehringer Ingelheim

Completed

DDI Strong CYP3A4 Inducer

Healthy

Germany
Medicure

Completed

MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)

Hypertension | Metabolic Syndrome | Diabetes Mellitus Type 2

Canada
Vanderbilt-Ingram Cancer Center

Withdrawn

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center

Completed

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Rectal Cancer

United States
University Hospital, Montpellier
Club anesthésie Reanimation Obstetricale

Completed

Oral Self Medication Versus IV Administration of Pain Killers After Caesarian Delivery

Caesarian Section

France
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

Peripheral T Cell Lymphoma | Treatment-naïve

China
Jonsson Comprehensive Cancer Center
Daiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.S

Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Invasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast Cancer

United States
University Medical Center Mainz

Completed

IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases

Neurological Autoimmune Diseases

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 | Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8

United States
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Withdrawn

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Richter Syndrome | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recurrent Glioblastoma | Refractory Glioblastoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma

United States
Boehringer Ingelheim

Completed

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Healthy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States

Search clinical trials for: BI-1206 single agent expansion phase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations